Chronopharmaceuticals: Hype or future of pharmaceutics

Current Pharmaceutical Design

Volumn 17, Issue 15, 2011, Pages 1512-1516

  Philip, Anil K ^a   Philip, Betty ^a  

^a UNIVERSITY OF NIZWA   (Oman)

Author keywords

Chronopharmaceuticals; Chronopharmacokinetics; Circadian; Models; Oscillation

Indexed keywords

CHRONOBIOLOGY; CHRONOPHARMACEUTICS; DRUG DELIVERY SYSTEM; NANOTECHNOLOGY; PHARMACEUTICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG CHRONOTHERAPY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS;

EID: 84856266039     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796197151     Document Type: Review

References (57)

1. Aulton M, Ed. Pharmaceutics: The science of dosage form design. New York: Churchill Livingstone 2002.
2. Stevens HNE. Chronopharmaceutical drug delivery. J Pharm Pharmacol 1998; 50: s5
3. Cornelissen G, Halberg E, Halberg F, et al. Chronobiology: a frontier in biology and medicine. Chronobiologia 1989; 16: 383-408.
4. Lemmer B. Chronobiology, drug-delivery, and chronotherapeutics. Adv Drug Del Rev 2007; 59: 825-827.
5. Labrecque G, Beauchamp D. In: Redfern P, Ed. Rhythms and pharmacokinetics. London: Pharmaceutical Press. 2003; pp. 75-6.
6. Youan B. Chronopharmaceutics: Gimmick or clinically relevant approach to drug delivery. J Control Release 2004; 98: 337-53.
7. Reinberg A, Smolensky MH. Circadian changes in drug disposition in man. Clin Pharmacokinet 1982; 7: 401-20.
8. Rao BR, Rambhau D. Chronopharmacokinetics of sulphamethoxazole in human volunteers. Drug Invest 1992; 4: 199-204.
9. Ohdo S. Chrono-drug-delivery focused on biological clock: intraand inter-individual variability of molecular clock. Adv Drug Del Rev 2010; 62: 857-8.
10. Okamura H, Doi M, Fustin JM, Yamaguchi Y, Matsuo M. Mammalian circadian clock system: Molecular mechanisms for pharmaceutical and medical sciences. Adv Drug Del Rev 2010; 62: 876-84.
11. Youan Bi BC, Ed. Chronopharmaceutics: Science and technology for biological rhythm guided therapy and prevention of diseases. New Jersy: Wiley 2009.
12. Paschos GK, Baggs JE, Hogenesch JB, FitzGerald GA. The role of clock genes in pharmacology. Annu Rev Pharmacol Toxicol 2010; 50: 187-214.
13. Nagar M, Singhai S, Chopra VS, et al. Chronotropic systems; an emerging trend in drug delivery for pulsed release in chronopharmacotherapy. Int J Pharm Clin Res 2010; 2: 10-19.
14. Belgamwar VS, Gaikwad MV, Patil GB, Surana S. Pulsatile drug delivery system. Asian J Pharm 2008; 2: 141-5.
15. Macey SL, Ed. Encyclopedia of time. New York: Taylor and Francis 1994. 16.
16. Medicinenet.com. New York: MedicineNet, Inc. ©1996-2009 [cited June 20 2010] Available from: http://www.medicinenet.com/biorhythms/article.htm
17. Cutolo M, Villaggio B, Otsa K, Aakre O, Sulli A, Seriolo B. Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease??s symptoms. Autoimmun Rev 2005; 4: 497-502.
18. Wagner S, Gladziwa U, Gebel M, Schuler, Freise J, Schmidt F. Circadian pattern of intragastric acidity in duodenal ulcer patients: A study of variations in relation to ulcer activity, Gut 1991; 32: 1104-9.
19. Jha N, Bapat S. Chronobiology and chronotherapeutics. Kathmandu Univ Med J 2004; 2: 384-8.
20. Lemmer B. The importance of circardin rhythms on drug response in hypertension and coronary heart disease-from mice and man. Pharmacol Ther 2006; 111 (3): 629-51.
21. Mormont MC, Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer 2003; 97(1): 155-69.
22. Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Del Rev 2007; 59: 828-51.
23. Kalsbeek A, Palm, IF, La Fleur SE, et al. SCN outputs and the hypothalamic balance of life. J Biol Rhythms 2006; 21: 458-69.
24. Kalsbeek A, Palm, IF, La Fleur SE, et al. The Circadian System of Man, Results of Experiments under Temporal Isolation, Springer- Verlag, New York, 1979, pp. 276.
25. Reinberg A. (Ed.), Chronobiologic Field Trials of Oil Refinery Shift Workers, Chronobiologia, vol. 1 (Suppl 1), 1979, pp. 119
26. Khalsa SB, Jewett ME, Cajochen C, Czeisler CA. A phase response curve to single bright light pulses in human subjects, J Physiol 2003; 549: 945-52.
27. Lynch HJ, Rivest RW, Wurtman RJ. Artificial induction of melatonin rhythms by programmed microinfusion. Neuroendocri-nology 1980; 31: 106-11.
28. Theeuwes F, Yum SI, Haak R, Wong P. Systems for triggered, pulsed, and programmed drug delivery. Ann N Y Acad Sci 1991; 618: 428-40.
29. Levi FA, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-17.
30. Levi FA, Zidani R, Vannetzel JM, Perpoint B, et al. Pharmacoeconomic comparative evaluation of combination chronotherapy vs. standard chemotherapy for colorectal cancer. Chronobilogy Int 2002; 19: 289-97.
31. Giannos SA, Dinh SM, Berner B. Polymeric substitution in a pH oscillator. Macro Rapid Comm 2003; 7: 527-31.
32. Misra GP, Siegel RA. Ionizable Drugs and pH Oscillators. Buffer Effects. J Pharm Sci 2002; 91: 2003-15
33. Misra GP, Siegel RA. Multipulse Drug Permeation across a Membrane Driven by a pH-Oscillator. J Control Rel 2002; 79: 293-97.
34. Staples M, Daniel K, Cima MJ, Langer R. A pplication of Microand Nano-Electromechanical Devices to Drug Delivery. Pharm Res 2006; 23: 847-63.
35. Clairambault J, Gaubert S, Lepoutre T. Comparison of Perron and Floquet eigenvalues in age structured cell division cycle models. Math Model Nat Phenom 2009; 4: 183-209.
36. Betancourt-Mar JA, Nieto-Villar JM. Theoretical models for chronotherapy: periodic perturbations in funnel chaos type. Math Biosci Eng 2007; 4: 177-86.
37. Anderson DG, Burdick JA, Langer R. Materials science. Smart biomaterials Sci 2004; 305: 1923-4.
38. Langer R, Tirrell DA, Designing materials for biology and medicine. Nature 2004; 428: 487-92.
39. Santini Jr JT, Cima MJ, Langer R, A controlled-release microchip. Nature 1999; 397: 335-8.
40. Wesley RB, Feringa BL, Making molecular machines work. Nat Nanotechnol 2006; 1: 25-35.
41. Youan BBC. Chronopharmaceutical drug delivery systems: Hurdles, hype or hope? Adv Drug Del Rev 2010; 62: 898-903.
42. Youan BBC (Ed.), Chronopharmaceutics: Science and Technology for Biological Rhythm Guided Therapy and Prevention of Diseases, John Wiley & Sons, Hoboken, NJ, USA, 2009.
43. Kitano H. A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 2007; 6: 202-10.
44. Goldbeter A, Computational approaches to cellular rhythms. Nature 2002; 420: 238-45.
45. Marroum P. Development and evaluation of controlled release products with emerging technologies. Amer Pharm Rev 2009; 147-9.
46. FDA, s for approval of a new indication for, or other change from, a listed drug, 21 CFR 314.54, 2009.
47. McCormick CG, Regulatory challenges for new formulations of controlled substances in today's environment, Drug Alcohol Depend 2006; 83: S63-7.
48. FDA, Approval with restrictions to assure safe use, 21 CFR314.520, 2009.
49. Boissanade J. Oscillatory dynamics induced in polyelectrolyte gels by a nonoscillatory reactions: a model. Eur Phys J 2009; 28: 337-46.
50. Tigges M, Marquez-Lago TT, Stelling J, Fussenegger M. A tunable synthetic mammalian oscillator. Nature 2009; 457: 309-12.
51. Liu T, Liu X, Chen Y, Wu R. A computational model for functional mapping of genes that regulate intra-cellular circadian rhythms. Theor Biol Med Model 2007; 4: 5.
52. Mirsky HP, Liu AC, Welsh DK, Kay SA, Doyle FJ III. A model of the cell autonomous mammalian circadian clock. Proc Natl Acad Sci USA 2009; 106: 11107-12.
53. Kitano H. Systems biology: a brief overview. Science 2002; 295: 1662-4.
54. Ueda HR, Systems biology of mammalian circadian clocks. Cold Spring Harb Symp Quant Biol 2007; 72: 365-80.
55. Levi F, Filipski E, Iurisci I, Li XM, Innominato P. Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp Quant Biol 2007; 72: 465-75.
56. LaVan DA, Lynn DM, Langer R. Moving smaller in drug discovery and delivery. Nat Rev Drug Discov 2002; 1: 77-84.
57. Youan BB. Impact of nanoscience and nanotechnology on controlled drug delivery. Nanomedicine 2008; 3: 401-6.